BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 19087082)

  • 1. Fertility-sparing treatment in young women with endometrial cancer or atypical complex hyperplasia: a prospective single-institution experience of 21 cases.
    Signorelli M; Caspani G; Bonazzi C; Chiappa V; Perego P; Mangioni C
    BJOG; 2009 Jan; 116(1):114-8. PubMed ID: 19087082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Outcome analysis of conservative treatment of well-differentiated endometrial adenocarcinoma and severe atypical hyperplasia in young women].
    Yu M; Shen K; Yang JX; Huang HF; Wu M; Pan LY; Lang JH; Lian LJ
    Zhonghua Fu Chan Ke Za Zhi; 2006 Apr; 41(4):242-5. PubMed ID: 16759458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased natural killer cells and decreased regulatory T cells are seen in complex atypical endometrial hyperplasia and well-differentiated carcinoma treated with progestins.
    Witkiewicz AK; McConnell T; Potoczek M; Emmons RV; Kurman RJ
    Hum Pathol; 2010 Jan; 41(1):26-32. PubMed ID: 19733383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fertility-sparing treatment of endometrial cancer precursors among young women: a reproductive point of view.
    Ricciardi E; Maniglio P; Frega A; Marci R; Caserta D; Moscarini M
    Eur Rev Med Pharmacol Sci; 2012 Dec; 16(14):1934-7. PubMed ID: 23242719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fertility sparing treatment of complex atypical hyperplasia and low grade endometrial cancer using oral progestin.
    Simpson AN; Feigenberg T; Clarke BA; Gien LT; Ismiil N; Laframboise S; Massey C; Ferguson SE
    Gynecol Oncol; 2014 May; 133(2):229-33. PubMed ID: 24561246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pregnant rate and pregnancy-relating factors of patients with early endometrial carcinoma and severe atypical hyperplasia of endometrium after fertility-preserving treatment by progestin].
    Cao DY; Yu M; Yang JX; Shen K; Huang HF; Cheng NH; Sun ZY; Deng CY; Yu Q; He FF
    Zhonghua Fu Chan Ke Za Zhi; 2013 Jul; 48(7):519-22. PubMed ID: 24284224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women.
    Ushijima K; Yahata H; Yoshikawa H; Konishi I; Yasugi T; Saito T; Nakanishi T; Sasaki H; Saji F; Iwasaka T; Hatae M; Kodama S; Saito T; Terakawa N; Yaegashi N; Hiura M; Sakamoto A; Tsuda H; Fukunaga M; Kamura T
    J Clin Oncol; 2007 Jul; 25(19):2798-803. PubMed ID: 17602085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fertility-preserving treatment with progestin, and pathological criteria to predict responses, in young women with endometrial cancer.
    Yamazawa K; Hirai M; Fujito A; Nishi H; Terauchi F; Ishikura H; Shozu M; Isaka K
    Hum Reprod; 2007 Jul; 22(7):1953-8. PubMed ID: 17449880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of fertility-preserving treatment in young women with endometrial carcinomas.
    Niwa K; Tagami K; Lian Z; Onogi K; Mori H; Tamaya T
    BJOG; 2005 Mar; 112(3):317-20. PubMed ID: 15713146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fertility-preserving treatment in young women with well-differentiated endometrial carcinoma and severe atypical hyperplasia of endometrium.
    Yu M; Yang JX; Wu M; Lang JH; Huo Z; Shen K
    Fertil Steril; 2009 Dec; 92(6):2122-4. PubMed ID: 19591991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histologic alterations in endometrial hyperplasia and well-differentiated carcinoma treated with progestins.
    Wheeler DT; Bristow RE; Kurman RJ
    Am J Surg Pathol; 2007 Jul; 31(7):988-98. PubMed ID: 17592264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Young women with atypical endometrial hyperplasia or endometrial adenocarcinoma stage I: will conservative treatment allow pregnancy? Results of a French multicentric survey].
    Le Digabel JF; Gariel C; Catala L; Dhainaut C; Madelenat P; Descamps P
    Gynecol Obstet Fertil; 2006 Jan; 34(1):27-33. PubMed ID: 16406735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reproductive and oncologic outcomes after progestin therapy for endometrial complex atypical hyperplasia or carcinoma.
    Kudesia R; Singer T; Caputo TA; Holcomb KM; Kligman I; Rosenwaks Z; Gupta D
    Am J Obstet Gynecol; 2014 Mar; 210(3):255.e1-4. PubMed ID: 24211482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncologic and reproductive outcomes after fertility-sparing management with oral progestin for women with complex endometrial hyperplasia and endometrial cancer.
    Chen M; Jin Y; Li Y; Bi Y; Shan Y; Pan L
    Int J Gynaecol Obstet; 2016 Jan; 132(1):34-8. PubMed ID: 26493012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The fertility-sparing treatment in patients with endometrial atypical hyperplasia and early endometrial cancer: a debated therapeutic option.
    Gadducci A; Spirito N; Baroni E; Tana R; Genazzani AR
    Gynecol Endocrinol; 2009 Oct; 25(10):683-91. PubMed ID: 19562604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG 2002).
    Park JY; Kim DY; Kim JH; Kim YM; Kim KR; Kim YT; Seong SJ; Kim TJ; Kim JW; Kim SM; Bae DS; Nam JH
    Eur J Cancer; 2013 Mar; 49(4):868-74. PubMed ID: 23072814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of high-dose progestin and long-term outcomes in young women with early-stage, well-differentiated endometrioid adenocarcinoma of uterine endometrium.
    Park H; Seok JM; Yoon BS; Seong SJ; Kim JY; Shim JY; Park CT
    Arch Gynecol Obstet; 2012 Feb; 285(2):473-8. PubMed ID: 21706284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effects of pathological assessment of endometrial tissue in fertility-sparing treatment with progestin for endometrial carcinoma of stage I a and complex atypical hyperplasia].
    Gong Q; Chen X; Xie X
    Zhonghua Fu Chan Ke Za Zhi; 2014 Sep; 49(9):664-9. PubMed ID: 25487452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reevaluating the safety of fertility-sparing hormonal therapy for early endometrial cancer.
    Yang YC; Wu CC; Chen CP; Chang CL; Wang KL
    Gynecol Oncol; 2005 Nov; 99(2):287-93. PubMed ID: 16051341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of metastatic endometrial endometrioid adenocarcinoma while on progestin therapy for endometrial hyperplasia.
    Rubatt JM; Slomovitz BM; Burke TW; Broaddus RR
    Gynecol Oncol; 2005 Nov; 99(2):472-6. PubMed ID: 16099019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.